A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
NCT07005102Phase 2/3Recruiting
- Lead sponsor
- AbbVie (Industry)
- Enrollment
- 854 (estimated)
- Start date
- 3 Aug 2025
- Primary completion
- Nov 2036 (estimated)
- Study completion
- 1 Nov 2036
- Last update posted
- 5 Oct 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Sequential
- Masking
- Quadruple
- Arms
- 7
Interventions
- Standard of Care Drug
- Telisotuzumab Adizutecan Drug
- Osimertinib (Osi) Drug
- Cisplatin Drug
- Carboplatin Drug
- Pemetrexed Drug
Conditions and primary outcome
- Non-Squamous Non-Small Cell Lung Cancer
- c-MET
Primary outcome
Stage 1: Objective Response (OR) Based on Blinded Independent Central Review (BICR) Assessment per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (Up to Approximately 76 Months); Stage 2: Progression-free survival (PFS) based on BICR assessment per RECIST version 1.1. (Up to Approximately 76 Months); Number of Participants with Adverse Events (AEs) (Up to Approximately 76 Months)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT07005102.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT07005102 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.